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Objectives: One of the most common head and neck cancers is nasopharynx
cancer. Knowledge about the incidence and mortality of this disease and its
distribution in terms of geographical areas is necessary for further study and
better planning. Therefore, this study was conducted with the aim of deter-
mining the incidence and mortality rates of nasopharynx cancer and its rela-
tionship with the Human Development Index (HDI) in Asia in 2012.
Methods: The aim of this ecologic study was to assess the correlation between
age-specific incidence rate (ASIR) and age-specific mortality rate (ASMR) with HDI
and its components, which include the following: life expectancy at birth, mean
years of schooling, and gross national income per capita. Data about SIR and SMR
for every Asian country for 2012 were obtained from the global cancer project.
We used the correlation bivariate method for the assessment. Statistical signif-
icance was assumed if p < 0.05. All reported p values are two-sided. Statistical
analyses were performed using SPSS (Version 15.0, SPSS Inc.).
Results: A total of 68,272 cases (males, 71.02%; females, 28.97%; sex ratio, 2.45)
and 40,530 mortalities (males, 71.63%; females, 28.36%; sex ratio, 2.52) were
recorded in Asian countries in 2012. The five countries with the highest ASIR of
nasopharynx cancer were Malaysia, Singapore, Indonesia, Vietnam, and Brunei,
and the five countries with the highest ASMR were Indonesia, Vietnam,iniya).
ase Control and Prevention. Published by Elsevier Korea LLC. This is an open access article
reativecommons.org/licenses/by-nc-nd/4.0/).
Nasopharynx cancer in Asia 361Singapore, Malaysia, and Brunei. The correlation between HDI and ASIR was 0.097
(pZ 0.520) [0.105 in men (pZ 0.488) and 0.119 in women (pZ 0.901)]. The
correlation between HDI and ASMR was e0.102 (pZ 0.502) [e0.072 in men
(pZ 0.633) and e0.224 in women (pZ 0.134)].
Conclusion: Nasopharynx cancer is native to Southeast Asia. The highest inci-
dence and mortality rates are found in Malaysia, Singapore, Indonesia, Vietnam,
and Brunei. No significant relation was found between the standardized inci-
dence and mortality rates of nasopharynx cancer and the HDI components.
Further studies are recommended in Southeast Asian countries in order to find
the etiology of cancer, as well as its diagnosis and treatment.1. Introduction
Cancer is the leading cause of mortality, with a high
financial burden, and one of the major public health
concerns at the international level [1,2]. Head and neck
malignancies are among the relatively common cancers
in humans that affect several anatomic sites of the head
and the neck [3]. One of the most common head and
neck cancers is nasopharynx cancer [4,5], which has a
very unique distribution pattern. Worldwide, about
86,500 cases of nasopharynx cancer and 50,000 deaths
arising from it [6] are reported annually. According to
the International Agency for Research on Cancer report
in 2008, more than 80% of patients with nasopharynx
cancer are in Asia, and only 5% of these cancers are
reported in Europe. Specifically, 71% of new naso-
pharynx cancer cases are recorded in East and Southeast
Asia, and 29% are diagnosed in South and Central Asia
and North and East Africa [7].
Nasopharynx cancer is native to Southeast Asia,
where the prevalence rate is 15e50 cases per 100,000
people [8]. For the United States and the rest of the
world, the incidence of less than 1 case per 100,000
people per year is reported [9]. In addition to geographic
diversity, it seems that some ethnic groups are prone to
nasopharynx cancer. These groups include the Bidayuh
in Borneo, the Nagas in northern India, and the Inuits in
the North pole, which have an age-standardized inci-
dence rate of more than 16 per 100,000 people among
men each year [10].
In terms of heterogeneous epidemiological patterns,
in addition to nonenvironmental risk factors such as sex,
ethnicity, and family history [11], other factorsdsuch as
smoking [12], salted fish consumption, especially in
childhood [12e18], nitrosamine in some food items
traditionally used in southern China [19,20], and use of
traditional herbal medicines in the Asian population
[12,21e23], as well as nonfood risk factors such as
occupational exposures to formaldehyde, wood dust,
smoke, and chemicals [7,12,22,24]dmay be involved in
the pathogenesis of nasopharynx carcinoma [25].
Nasopharynx cancer, in comparison to other head and
neck tumors, has different epidemiological, staging, andtreatment characteristics. Most patients are diagnosed
when they are in advanced stages [26,27].
The Human Development Index (HDI) is a useful tool
to compare the incidence and mortality rates of cancer at
the global level [28e30] and is one of the indicators to
check the status of illnesses and deaths between coun-
tries. In fact, this index has been observed to be related
with the incidence and mortality rates of many diseases;
it is considered a good index to obtain information
regarding the status of a specific disease in different
countries. The HDI is composed of three basic di-
mensions: life expectancy at birth, adult literacy rate, and
gross domestic product (GDP) per capita. The relation-
ship between HDI and some cancers is studied, and
investigating this relationship can lead to a more accurate
understanding of cancer and its risk factors distribution
[31], and it is also suggested to be used for other cancers.
Although nutritional and communicable diseases are
common causes of death in countries with a low HDI, it is
anticipated that by 2030, one common cause of death in
these countries will be noncommunicable diseases such
as cancer [32]. Because awareness about nasopharynx
cancer incidence and mortality can be useful for health
programs and research activities, and considering the
possible role of the HDI, this study was conducted with
the aim of evaluating the incidence and mortality of
nasopharynx carcinoma and its relationship with the
development index and its components in Asia in 2012.2. Materials and methods
We conducted an ecologic study in Asia to assess the
correlation between age-specific incidence and mortality
rate (ASR) with HDI and its components, which include
the following: life expectancy at birth, mean years of
schooling, and gross national income (GNI) per capita.
The ASR data of all Asian countries for the year 2012
were obtained from the global cancer project (available
at http://globocan.iarc.fr/Default.aspx) [33], and the
HDI data was based on the Human Development Report
2013 [34], which contains information about HDI and its
components for every country in the world in 2012.
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2.1.1. Age-specific incidence rate estimate
The methods of estimation are country-specific, and
the quality of the estimation depends on the quality and
amount of information available for each country. In
theory, there are as many methods as countries, and
because of the variety and the complexity of these
methods, an overall quality score for the incidence and
mortality estimates combined is almost impossible to
establish. However, an alphanumeric scoring system that
independently describes the availability of incidence and
mortality data has been established at the country level.
The combined score is presented together with the esti-
mates for each country with the aim of providing a broad
indication of the robustness of the estimation.
The methods used to estimate the sex- and age-
specific incidence rates of cancer for a specific country
fall into one of the following broad categories (by order
of priority):
1. Rates projected to 2012 (38 countries).
2. Most recent rates applied to 2012 population (20
countries).
3. Estimated from national mortality by modeling, using
incidence mortality ratios derived from recorded data
in country-specific cancer registries (13 countries).
4. Estimated from national mortality estimates by
modeling, using incidence mortality ratios derived
from recorded data in local cancer registries in
neighboring countries (9 European countries).
5. Estimated from national mortality estimates using
modeled survival (32 countries)
6. Estimated as the weighted average of the local rates
(16 countries)
7. One cancer registry covering part of a country is used
as representative of the country profile (11 countries).
8. Age/sex-specific rates for “all cancers” were parti-
tioned using data on relative frequency of different
cancers (by age and sex) (12 countries).
9. The rates are those of neighboring countries or reg-
istries in the same area (33 countries) [33,35].
2.1.2. Age-specific mortality rate estimate
Depending on the degree of detail and accuracy of
the national mortality data, six methods were used in the
following order of priority:
1. Rates projected to 2012 (69 countries).
2. Most recent rates applied to 2012 population (26
countries).
3. Estimated as the weighted average of regional rates
(1 country).
4. Estimated from national incidence estimates by
modeling, using country-specific survival (2
countries).5. Estimated from national incidence estimates using
modeled survival (83 countries).
6. The rates are those of neighboring countries or reg-
istries in the same area (3 countries) [33,35].
2.2. Human Development Index
HDI is a composite measure of indicators along three
dimensions: life expectancy, educational attainment, and
command over the resources needed for a decent living.
All groups and regions have seen notable improvement
in all HDI components, with faster progress in low and
medium HDI countries. On this basis, the world is
becoming less unequal. Nevertheless, national averages
hide large variations in human experience. Wide dis-
parities remain within countries of both the North and
the South, and income inequality within and between
many countries has been rising [34].
2.3. Statistical analysis
In this study, we used the correlation bivariate
method to assess the correlation between ASR and HDI
and its components (life expectancy at birth, mean years
of schooling, and GNI per capita). Statistical signifi-
cance was assumed if p < 0.05. All reported p values are
two-sided. Statistical analyses were performed using
SPSS (Version 15.0: SPSS Inc., Chicago).3. Results
In general, a total of 68,272 nasopharynx cancer
cases were recorded in Asian countries in 2012, of
which 48,492 cases (2/71%) were diagnosed in men and
19,780 cases (97/28%) were diagnosed in women. These
figures indicate that the sex (male/female) ratio is 45:2.
Five countries with the highest number of new cases of
nasopharynx cancer are as follows: (1) China with
33,198 cases; (2) Indonesia, 13,084 cases; (3) Vietnam,
4,931 cases; (4) India, 3,947 cases; (5) Malaysia, 2,030
cases; these five countries alone accounted for a total of
57,190 cases (76/83%) of all cases in Asia. In Asia, the
five countries with the highest standardized incidence of
nasopharynx cancer are as follows: (1) Malaysia, with a
standardized rate of 7.2 per 100,000 people; (2)
Singapore, 6.4 per 100,000 people; (3) Indonesia, 5.6
per 100,000 people; (4) Vietnam, 5.4 per 100,000 peo-
ple; (5) Brunei, 5 per 100,000 people. Conversely, the
five countries with the lowest standardized incidence of
nasopharynx cancer are as follows: (1) Maldives, with a
rate of 0 per 100,000 people; (2) Tajikistan, 0.1 per
100,000 people; (3) Japan, 0.2 per 100,000 people; (4)
Bahrain, 0.2 per 100,000 people; (5) Uzbekistan, 0.3 per
100,000 people. The number and rate of standardized
and crude incidence of this cancer in Asian countries
according to sex are shown in Table 1. Countries are
arranged based on standardized rates, from highest to
lowest, in Table 1, so that countries with the highest and
Table 1. Number and amount of standardized and crude incidence of nasopharynx cancer in Asian countries in 2012 (sorted by age-standardized incidence rate, from the highest to the
lowest value).
Nasopharynxdestimated
incidence, all ages: both sexes
Nasopharynxdestimated
incidence, all ages: male
Nasopharynxdestimated
incidence, all ages: female
Population No. Crude rate
Age-world-
standardized
incidence
rate
(ASR(W)) Population No. Crude rate
Age-world-
standardized
incidence
rate
(ASR(W)) Population No. Crude rate ASR (W)
Malaysia 2,030 6.9 7.2 Malaysia 1,487 10.0 10.6 Malaysia 543 3.8 3.9
Singapore 473 9.0 6.4 Singapore 353 13.3 9.7 Vietnam 1,630 3.6 3.4
Indonesia 13,084 5.3 5.6 Indonesia 9,355 7.7 8.3 Singapore 120 4.6 3.2
Vietnam 4,931 5.5 5.4 Vietnam 3,301 7.4 7.7 Indonesia 3,729 3.0 3.0
Brunei 15 3.6 5.0 Brunei 12 5.8 7.6 Bhutan 6 1.7 1.9
Myanmar 1,148 2.4 2.4 Myanmar 789 3.3 3.5 Brunei 3 1.5 1.5
Philippines 1,738 1.8 2.2 Cambodia 159 2.2 3.3 Myanmar 359 1.5 1.5
Bhutan 14 1.9 2.2 Philippines 1,199 2.5 3.2 Philippines 539 1.1 1.3
Thailand 1,867 2.7 2.1 Thailand 1,328 3.9 3.2 Thailand 539 1.5 1.2
China 33,198 2.4 1.9 China 23,581 3.3 2.7 China 9,617 1.5 1.1
Cambodia 220 1.5 1.9 Bhutan 8 2.0 2.5 Yemen 96 0.8 1.1
Lao PDR 81 1.3 1.7 Lao PDR 55 1.7 2.5 Lao PDR 26 0.8 1.0
Yemen 217 0.8 1.5 Timor-Leste 7 1.2 1.9 Cambodia 61 0.8 0.9
Saudi Arabia 295 1.0 1.3 Yemen 121 0.9 1.8 Saudi Arabia 83 0.6 0.9
Korea, Democratic
Republic of
383 1.6 1.3 Korea, Democratic
Republic of
244 2.0 1.8 Korea, Democratic
Republic of
139 1.1 0.8
Timor-Leste 9 0.8 1.2 Saudi Arabia 212 1.3 1.7 Jordan 19 0.6 0.8
Jordan 51 0.8 1.1 Georgia 46 2.3 1.7 Kuwait 4 0.3 0.6
Turkey 779 1.0 1.0 Nepal 178 1.2 1.6 Syrian Arab Republic 51 0.5 0.6
Nepal 233 0.8 1.0 Turkey 588 1.6 1.6 Turkey 191 0.5 0.5
Georgia 57 1.3 0.9 Jordan 32 1.0 1.3 Iraq 56 0.3 0.5
Syrian Arab Republic 138 0.7 0.8 Armenia 19 1.3 1.2 Timor-Leste 2 0.3 0.5
United Arab Emirates 36 0.4 0.8 Kyrgyzstan 25 0.9 1.1 Sri Lanka 50 0.5 0.4
Iraq 139 0.4 0.7 Syrian Arab Republic 87 0.8 1.1 Nepal 55 0.4 0.4
Qatar 10 0.5 0.7 Lebanon 23 1.1 1.1 Iran, Islamic
Republic of
140 0.4 0.4
Lebanon 31 0.7 0.7 Korea, Republic of 320 1.3 1.0 United Arab
Emirates
10 0.4 0.4
Korea, Republic of 442 0.9 0.7 Israel 38 1.0 0.9 Korea, Republic of 122 0.5 0.4
Iran, Islamic Republic of 418 0.6 0.6 Iraq 83 0.5 0.9 Lebanon 8 0.4 0.3
Israel 53 0.7 0.6 United Arab Emirates 26 0.5 0.9 Pakistan 228 0.3 0.3
(Continued on next page )
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Table 1 (Continued )
Nasopharynxdestimated
incidence, all ages: both sexes
Nasopharynxdestimated
incidence, all ages: male
Nasopharynxdestimated
incidence, all ages: female
Population No. Crude rate
Age-world-
standardized
incidence
rate
(ASR(W)) Population No. Crude rate
Age-world-
standardized
incidence
rate
(ASR(W)) Population No. Crude rate ASR (W)
Kyrgyzstan 28 0.5 0.6 Qatar 9 0.6 0.8 Israel 15 0.4 0.3
Armenia 22 0.7 0.6 Iran, Islamic Republic
of
278 0.7 0.8 Georgia 11 0.5 0.3
Pakistan 795 0.4 0.6 State of Palestine 10 0.5 0.8 Mongolia 3 0.2 0.3
Kuwait 11 0.4 0.5 Pakistan 567 0.6 0.8 Kazakhstan 25 0.3 0.3
State of Palestine 14 0.3 0.5 Azerbaijan 34 0.7 0.7 Qatar 1 0.2 0.3
Kazakhstan 75 0.5 0.4 Kazakhstan 50 0.6 0.7 Uzbekistan 26 0.2 0.2
Azerbaijan 42 0.4 0.4 India 2,956 0.5 0.5 Oman 2 0.2 0.2
Sri Lanka 95 0.4 0.4 Bangladesh 322 0.4 0.5 Bahrain 1 0.2 0.2
Oman 9 0.3 0.4 Oman 7 0.4 0.5 Bangladesh 112 0.1 0.2
Mongolia 8 0.3 0.4 Afghanistan 51 0.3 0.5 India 991 0.2 0.2
India 3,947 0.3 0.4 Turkmenistan 9 0.4 0.4 State of Palestine 4 0.2 0.2
Bangladesh 434 0.3 0.3 Mongolia 5 0.4 0.4 Azerbaijan 8 0.2 0.2
Afghanistan 66 0.2 0.3 Japan 421 0.7 0.4 Afghanistan 15 0.1 0.2
Turkmenistan 11 0.2 0.3 Sri Lanka 45 0.4 0.4 Armenia 3 0.2 0.1
Uzbekistan 64 0.2 0.3 Kuwait 7 0.4 0.4 Kyrgyzstan 3 0.1 0.1
Bahrain 4 0.3 0.2 Uzbekistan 38 0.3 0.3 Turkmenistan 2 0.1 0.1
Japan 553 0.4 0.2 Bahrain 3 0.4 0.2 Japan 132 0.2 0.1
Tajikistan 4 0.1 0.1 Tajikistan 4 0.1 0.1 Maldives 0 0.0 0.0
Maldives 0 0.0 0.0 Maldives 0 0.0 0.0 Tajikistan 0 0.0 0.0
ASRZ age-specific incidence and mortality rate.
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Figure 1. Distribution standardized incidence rate of nasopharynx cancer in Asia in 2012 (extracted from GLOBALCAN).
ASRZ age-specific incidence and mortality rate.
Figure 2. Standardized incidence and mortality rate of nasopharynx cancer in Asia in 2012 (extracted from GLOBALCAN).
HDIZ Human Development Index; LAO PDRZ Laos People’s Democratic Republic.
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Table 2. Number and amount of standardized and crude mortality of nasopharynx cancer in Asian countries in 2012 (sorted by age-standardized incidence rate, from the highest to the
lowest value).
Nasopharynxdestimated mortality,
all ages: both sexes
Nasopharynxdestimated mortality,
all ages: female Nasopharynxdestimated mortality, all ages: male
Population No. Crude rate
Age-world-
standardized incidence
rate (ASR(W)) Population Number Crude rate
Age-world-standardized
incidence
rate (ASR(W)) Population No. Crude rate ASR (W)
Indonesia 7,391 3.0 3.3 Indonesia 5,283 4.3 5.0 Vietnam 954 2.1 2.0
Vietnam 2,885 3.2 3.3 Vietnam 1,931 4.4 4.8 Indonesia 2,108 1.7 1.8
Singapore 218 4.1 2.8 Singapore 168 6.3 4.4 Bhutan 4 1.1 1.5
Malaysia 698 2.4 2.5 Malaysia 533 3.6 3.9 Singapore 50 1.9 1.3
Brunei 6 1.5 2.1 Brunei 5 2.4 3.4 Malaysia 165 1.1 1.2
Myanmar 785 1.6 1.8 Myanmar 538 2.2 2.6 Myanmar 247 1.0 1.1
Bhutan 8 1.1 1.4 Cambodia 105 1.5 2.5 Yemen 65 0.5 0.9
Cambodia 144 1.0 1.4 Thailand 793 2.3 1.9 Philippines 272 0.6 0.7
Philippines 873 0.9 1.3 Philippines 601 1.2 1.9 Lao PDR 16 0.5 0.7
Thailand 1,114 1.6 1.3 Lao PDR 35 1.1 1.7 Thailand 321 0.9 0.7
Lao PDR 51 0.8 1.2 Timor-Leste 6 1.0 1.7 China 5,686 0.9 0.6
China 20,404 1.5 1.2 China 14,718 2.1 1.7 Cambodia 39 0.5 0.6
Yemen 152 0.6 1.2 Yemen 87 0.7 1.5 Jordan 9 0.3 0.5
Timor-Leste 8 0.7 1.1 Bhutan 4 1.0 1.4 Timor-Leste 2 0.3 0.5
Nepal 164 0.5 0.8 Nepal 125 0.8 1.3 Saudi Arabia 38 0.3 0.5
Saudi Arabia 136 0.5 0.7 Korea, Democratic
Republic of
148 1.2 1.1 Brunei 1 0.5 0.5
Korea,
Democratic
Republic of
215 0.9 0.7 Saudi Arabia 98 0.6 0.9 Syrian Arab
Republic
29 0.3 0.4
Jordan 22 0.3 0.6 Turkey 300 0.8 0.9 Korea, Democratic
Republic of
67 0.5 0.4
Turkey 397 0.5 0.5 Georgia 22 1.1 0.8 Nepal 39 0.2 0.3
Syrian Arab
Republic
77 0.4 0.5 Kyrgyzstan 14 0.5 0.8 Iraq 32 0.2 0.3
Iraq 82 0.2 0.5 Syrian Arab Republic 48 0.4 0.7 Turkey 97 0.3 0.3
Qatar 4 0.2 0.4 Jordan 13 0.4 0.7 Pakistan 150 0.2 0.2
Georgia 27 0.6 0.4 Iraq 50 0.3 0.6 Iran, Islamic
Republic of
72 0.2 0.2
Pakistan 532 0.3 0.4 Armenia 10 0.7 0.6 Sri Lanka 26 0.2 0.2
Kyrgyzstan 16 0.3 0.4 Qatar 4 0.3 0.6 Afghanistan 12 0.1 0.2
United Arab
Emirates
13 0.2 0.4 Pakistan 382 0.4 0.6 United Arab
Emirates
3 0.1 0.2
Iran, Islamic
Republic of
214 0.3 0.3 Lebanon 12 0.6 0.5 Oman 1 0.1 0.1
Afghanistan 54 0.2 0.3 State of Palestine 6 0.3 0.5 Uzbekistan 14 0.1 0.1
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Nasopharynx cancer in Asia 367lowest standardized incidence rates in each sex are
shown (Table 1, Figures 1 and 2).
Of the 40,530 people who died of nasopharynx can-
cer in Asia in 2012, 29,032 (63/71%) were men and
11,498 (36/28%) were women, which translates to a
male/female mortality ratio of 52:2. The highest number
of deaths occurred in China with 20,404 cases, followed
by Indonesia with 7,391 cases, Vietnam with 2,885
cases, India with 2,836 cases, and Thailand with 1,114
cases. This brings the total of deaths to 34,630 (44/85%)
in just these five countries.
The five countries with the highest standardized mor-
tality rate of nasopharynx cancer are as follows: (1)
Indonesia, with a standardized rate of 3.3 per 100,000
people; (2) Vietnam, 3.3 per 1000,000 people; (3)
Singapore, 2.8 per 100,000 people; (4) Malaysia, 2.5 per
100,000 people; (5) Brunei, 2.1 per 100,000 people.
Conversely, the five countries with the lowest standardized
mortality rate of nasopharynx cancer are as follows:
Maldives and Tajikistan, with a rate of 0 per 100,000 peo-
ple; followed by Bahrain, Kuwait, and Israel with a rate of
0.1 per 100,000 people. The number and rate of standard-
ized and crudemortality of this cancer inAsian countries by
sex are shown in Table 2. Countries are arranged based on
standardized rates, from highest to lowest, in Table 2, so
that countrieswith thehighest and lowest standardized rates
in each sex are shown (Table 2 and Figures 2 and 3).
In Table 3, values of HDI and its components for all
Asian countries, arranged according to HDI, are shown.
Thus, Asian countries were classified in terms of HDI as
follows: three countries in very high category, four
countries in top category, 35 countries in the medium
category, three countries in low category, and a country
in uncertain category.3.1. Checking the relationship between
standardized incidence rate and HDI
A correlation of 0.097 was obtained between the
standardized incidence rate of nasopharynx cancer and
HDI; however, this relation was not statistically signif-
icant (pZ 0.520). As for the correlation between com-
ponents of the HDI and the standardized rate, we
obtained the following results: a correlation of 0.174
between the standardized incidence rate and life ex-
pectancy at birth (pZ 0.247), a negative correlation of
0.057 with the average years of schooling (pZ 0.705),
and a correlation of 0.134 with the level of income per
person of the population (pZ 0.375; Figure 4).
In men, a correlation of 0.105 was observed between
the standardized incidence rate of nasopharynx cancer
and the HDI; however, this relation was not statistically
significant (pZ 0.488).
A correlation was also seen between the components
of the HDI and the standardized incidence. Specifically,
we obtained a correlation of 0.174 between the stan-
dardized incidence rate and life expectancy at birth
Figure 3. Distribution standardized mortality rate of nasopharynx cancer in Asia in 2012 (extracted from GLOBALCAN).
HDIZ Human Development Index.
368 N. Mahdavifar, et al(pZ 0.253), a negative correlation of 0.031 with the
average years of schooling (pZ 0.836), and a correla-
tion of 0.125 with the level of income per person of the
population (pZ 0.407).
In women, a correlation of 0.019 was found between
the standardized incidence rate of nasopharynx cancer and
the HDI, but this relation was not statistically significant
(pZ 0.901). A correlation between components of the
HDI and the standardized incidence rate was also found.
Specifically, we noted a correlation of 0.134 between the
standardized incidence rate and life expectancy at birth
(pZ 0.376), a negative correlation of 0.142 with the
average years of schooling (pZ 0.346), and a correlation
of 0.059 with the level of income per person of the pop-
ulation (pZ 0.696).
3.2. Checking the relationship between
standardized mortality rate and HDI
A negative correlation of 0.102 was found between
the standardized mortality rate of nasopharynx cancer
and HDI; however, this relation was not statistically
significant (pZ 0.502). A correlation was also found
between components of the HDI and the standardized
rate. Specifically, we noted a correlation of 0.034 be-
tween the standardized incidence rate and life expec-
tancy at birth (pZ 0.824), a negative correlation of
0.238 with the average years of schooling (pZ 0.112),
and a correlation of 0.001 with the level of income per
person of the population (pZ 0.994; Figure 5).
In men, we observed a correlation of 0.072 between
the standardized mortality rate of nasopharynx cancerand the HDI, but this relation was not statistically sig-
nificant (pZ 0.633). Furthermore, a correlation be-
tween components of the HDI and standardized
mortality rate was also found. Specifically, we noted a
correlation of 0.040 between the standardized incidence
rate and life expectancy at birth (pZ 0.792), a negative
correlation of 0.188 with the average years of schooling
(pZ 0.211), and a correlation of 0.014 with the level of
income per person of the population (pZ 0.924).
In women, a negative correlation of 0.224 was found
between the standardized mortality rate of nasopharynx
cancer and the HDI, but this relation was not statistically
significant (pZ 0.134). Also, a negative correlation was
noted between components of the HDI and the stan-
dardized rate. Specifically, we observed a negative cor-
relation of 0.044 between the standardized incidence rate
and life expectancy at birth (pZ 0.773), a negative
correlation of 0.345 with the average years of schooling
(pZ 0.019), and a negative correlation of 0.014 with the
level of income per person of the population (pZ 0.350).4. Discussion
Overall, 68,272 new cases and 40,530 deaths attrib-
uted to nasopharynx cancer were recorded in Asian
countries in 2012; the sex (male/female) ratio of
developing the disease is 2.45, and the sex ratio of
nasopharynx cancer mortality is 2.52. The prevalence of
nasopharynx cancer in developing countries is higher,
and this is attributed to the higher exposure of
Table 3. Human Development Index (HDI) and its components in Asian countries in 2012.
Population HDI
Life expectancy
at birth
Mean years of
schooling GNI/capita
Very high human development Japan 0.912 83.6 11.6 32,545
Korea, Republic of 0.909 80.7 11.6 28,231
Israel 0.900 81.9 11.9 26,224
Singapore 0.895 81.2 10.1 52,613
Brunei 0.855 78.1 8.6 45,690
Qatar 0.834 78.5 7.3 87,478
United Arab Emirates 0.818 76.7 8.9 42,716
High human development Bahrain 0.796 75.2 9.4 19,154
Kuwait 0.790 74.7 6.1 52,793
Saudi Arabia 0.782 74.1 7.8 22,616
Malaysia 0.769 74.5 9.5 13,676
Kazakhstan 0.754 67.4 10.4 10,451
Georgia 0.745 73.9 12.1 5,005
Lebanon 0.745 72.8 7.9 12,364
Iran, Islamic Republic of 0.742 73.2 7.8 10,695
Azerbaijan 0.734 70.9 11.2 8,153
Oman 0.731 73.2 5.5 24,092
Armenia 0.729 74.4 10.8 5,540
Turkey 0.722 74.2 6.5 13,710
Sri Lanka 0.715 75.1 9.3 5,170
Medium human development Jordan 0.700 73.5 8.6 5,272
China 0.699 73.7 7.5 7,945
Turkmenistan 0.698 65.2 9.9 7,782
Thailand 0.690 74.3 6.6 7,722
Maldives 0.688 77.1 5.8 7,478
Mongolia 0.675 68.8 8.3 4,245
State of Palestine 0.670 73.0 8.0 3,359
Philippines 0.654 69.0 8.9 3,752
Uzbekistan 0.654 68.6 10 3,201
Syrian Arab Republic 0.648 76.0 5.7 4,674
Indonesia 0.629 69.8 5.8 4,154
Kyrgyzstan 0.622 68.0 9.3 2,009
Tajikistan 0.622 67.8 9.8 2,119
Vietnam 0.617 75.4 5.5 2,970
Iraq 0.590 69.6 5.6 3,557
Timor-Leste 0.576 62.9 4.4 5,446
India 0.554 65.8 4.4 3,285
Cambodia 0.543 63.6 5.8 2,095
Lao PDR 0.543 67.8 4.6 2,435
Bhutan 0.538 67.6 2.3 5,246
Low human development Bangladesh 0.515 69.2 4.8 1,785
Pakistan 0.515 65.7 4.9 2,566
Myanmar 0.498 65.7 3.9 1,817
Nepal 0.463 69.1 3.2 1,137
Yemen 0.458 65.9 5.3 928
Afghanistan 0.374 49.1 3.1 1,000
Other countries or territories Korea, Democratic
People’s Republic of
d d d d
GNIZ gross national income.
Nasopharynx cancer in Asia 369inhabitants to a variety of risk factors and lower
budget allocations for health. For these people, diag-
nosis is often made when the disease is already in
advanced stages, and, with the lack of access to treat-
ment, the metastasis of nasopharynx cancer can be
observed more often in these areas [36,37].In this study, no significant relationship was found
between the standardized incidence and mortality rate of
nasopharynx cancer and the HDI. Moreover, no signif-
icant positive relationship was observed between stan-
dardized incidence and mortality rate of nasopharynx
cancer with proper income level (GDP) and level of
Figure 4. Correlation between HDI and standardized incidence rate of nasopharynx cancer in Asia in 2012. ASRZ age-specific
incidence and mortality rate.
370 N. Mahdavifar, et aleducation or knowledge (mean years of schooling). In
other studies, the increase in life expectancy leads to an
increase in global cancer burden and future changes in
population growth and aging, indicating that new casesFigure 5. Correlation between HDI and standardized mortality ra
incidence and mortality rate.of nasopharynx cancer and mortality in elderly people
will increase and that this increase will be noticeable in
countries with low HDI compared to countries with high
HDI (76% vs. 25%) [26,28,38,39]. Furthermore,te of nasopharynx cancer in Asia in 2012. ASRZ age-specific
Nasopharynx cancer in Asia 371according to other studies, people who have higher ed-
ucation typically have more healthy habits and behav-
iors than those with a low education level, especially in
terms of cancer incidence and mortality [40,41]. In
studies focusing on nasopharynx cancer, the relationship
between nasopharynx cancer with socioeconomic status,
lifestyle, and geographical positions is known [12].
Thus, in Asian countries, there is an increased incidence
of nasopharynx cancer in lower economic classes,
especially among men [12]. Also, no difference was
found between the deaths of people living in rural areas
with low socioeconomic status and the people who live
in urban areas [42,43].
In this study, Malaysia, Singapore, Indonesia, Viet-
nam, and Brunei are the five countries with the highest
incidence rate. It is noteworthy that Singapore and
Brunei are classified as very high HDI countries,
Malaysia is considered a country with a high HDI, and
Indonesia and Vietnam are countries with medium HDI.
According to previous studies in Singapore, naso-
pharynx cancer is the eighth most common cancer in
men, with age-standardized incidence of 9.5 per 100,000
per year [44]. In Indonesia, a relatively high incidence is
reporteddat least 5.7 among men and 1.9 among
women per 100,000 peopledcompared with the global
incidence average of 1.9 among men and 0.8 among
women for every 100,000 individuals [45]. It should be
noted, however, that the actual incidence of naso-
pharynx cancer in Indonesia is not known owing to
incomplete registration [11].
Regardless of ethnicity, genetics plays an important
part in the pathogenesis of nasopharynx cancer. The
incidence of nasopharynx cancer is 20e50 times higher
in South China compared with Western countries. It is
notable that second and third generations of Chinese
people who immigrated to the United States (a low
prevalence area) are still at risk of high nasopharynx
cancer despite cultural assimilation compared with the
resident population [46]. In the present study, Indonesia,
Vietnam, Singapore, Malaysia, and Brunei were the five
countries with the highest death rates from this cancer.
Other studies have shown that one of the main causes of
death in Indonesia is nasopharynx cancer, and in early
detection, 80% of the patients are already at an advanced
stage of the disease. In Indonesia, primary healthcare is
generally handled by health centers named Puskesmas.
Lack of knowledge among the general practitioners
working in these centers regarding the various aspects of
nasopharynx cancer, may lead to a delay in diagnosis
[11]. Thus, only about 14% of patients who have
metastasis at the initial diagnosis and 29% of patients
without metastasis show response to therapy, about
70e95% response to therapy is good, so in general
response to the therapy is poor. [36]. In Singapore, older
patients diagnosed with stage 2 or stage 3 are at higher
risk of recurrence and lower overall survival [47].
Eighty percent of patients are now at stage 3 or 4 of thedisease, which leads to lower survival and death [11]. In
the past two decades, the treatment of nasopharynx
cancer has been considerably enhanced by the use of
chemotherapy and radiotherapy at the same time.
However, the overall incidence of patients with metas-
tasis remains at 25e34%, and survival of these patients
is low [48,49].5. Conclusion
Nasopharynx cancer is the native cancer of Southeast
Asia. So that the highest incidence and mortality are
related to Southeast Asian countries including Malaysia,
Singapore, Indonesia, Vietnam and Brunei. It was not
seen a significant relation between the standardized
incidence and mortality rate of nasopharynx cancer and
the Human Development Index components. Further
studies are recommended in Southeast Asian countries
in order to find the etiology of cancer, diagnosis and
treatment.
5.1. Limitations of the study
This was an ecological study. The ecological fallacy
will occur if results are inferred and concluded at the
individual level.Conflicts of interest
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